VRNA
Closed
Verona Pharma Plc Adr
26.39
-0.64 (-2.37%)
Last Update: 06 Sep 2024 23:00:00
Yesterday: 27.03
Day's Range: 25.5 - 27.39
Send
sign up or login to leave a comment!
When Written:
21.29
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases such as chronic obstructive pulmonary disease (COPD), cystic fibrosis, and asthma. The company's lead product candidate, RPL554, is a first-in-class, dual inhibitor of the enzymes phosphodiesterase 3 and 4. RPL554 is currently in Phase 3 clinical trials for the treatment of COPD and Phase 2 trials for the treatment of cystic fibrosis. Verona Pharma is headquartered in London, UK and has a listing on the NASDAQ stock exchange under the ticker symbol VRNA.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!